PARIS, France, September 6 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext : ALEHT), a drug and diagnostic discovery company, today announces that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571. It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.
